Bioenvision expands into Japan, Southeast Asia

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Bioenvision, Inc. is expanding into Japan and Southeast Asia for the clinical and commercial development of Evoltra (clofarabine), licensed from Southern Research Institute of Birmingham, Ala., the inventor of clofarabine.

The New York biopharmaceutical company had the option to develop, market and distribute clofarabine in Japan and Southeast Asia and converted it into an exclusive license. In Southeast Asia, Bioenvision licensed these rights in the countries of Indonesia, Malaysia, Taiwan, Hong Kong, Singapore, Vietnam, Cambodia, Thailand, Laos, Philippines and South Korea.

"Now that clofarabine has been approved in the U.S. and Europe, it is important for Bioenvision to establish a base of operations from which to develop clofarabine in Japan, the second largest pharmaceutical market in the world. Bioenvision's strategy is to develop clofarabine across therapeutic areas and across geographic locations. Succeeding to the Japanese rights is a critical step in this strategy," chief financial officer and general counsel David P. Luci said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.